Late occurrence of hepatic veno-occlusive disease following gemtuzumab ozogamicin: successful treatment with defibrotide

被引：11
|
作者：
Saviola, A [1 ]
Luppi, M [1 ]
Potenza, L [1 ]
Morselli, M [1 ]
Ferrari, A [1 ]
Riva, G [1 ]
Torelli, G [1 ]
机构：
[1] Univ Modena & Reggio Emilia, Sect Haematol, Dept Haematol & Oncol, I-4100 Modena, Italy
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2003年 / 123卷 / 04期
关键词：
veno-occlusive disease; leukaemia; gemtuzumab ozogamicin; defibrotide; Mylotarg;
D O I：
10.1046/j.1365-2141.2003.04667.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：752 / 753
页数：2
相关论文
共 50 条
  • [41] Final results of a multivariate logistic regression analysis to determine factors contributing to the risk of developing hepatic veno-occlusive disease (VOD) following treatment with gemtuzumab ozogamicin.
    Erba, HP
    Stadtmauer, EA
    Larson, RA
    Sievers, EL
    Estey, EH
    Löwenberg, B
    Leopold, LH
    Berger, MS
    Herbertson, R
    Appelbaum, FR
    BLOOD, 2002, 100 (11) : 339A - 339A
  • [42] EFFICACY AND SAFETY OF DEFIBROTIDE IN THE TREATMENT OF HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) FOLLOWING CHEMOTHERAPY
    Kernan, Nancy A.
    Richardson, Paul G.
    Triplett, Brandon M.
    Grupp, Stephan A.
    Antin, Joseph H.
    Messinger, Yoav
    Liang, Wei
    Hume, Robin
    Hannah, Alison L.
    Soiffer, Robert J.
    PEDIATRIC BLOOD & CANCER, 2016, 63 : S92 - S93
  • [43] Gemtuzumab ozogamicin (Mylotarg) prior to allogeneic hematopoietic stem cell transplantation increases the risk of hepatic veno-occlusive disease.
    Goldberg, SL
    Ellent, D
    Shtrambrand, D
    Abdo-Matkiwsky, M
    Hamarman, S
    Hsu, JW
    Rowley, SD
    Pecora, AL
    BLOOD, 2002, 100 (11) : 415A - 415A
  • [44] A single centre experience in Veno-occlusive disease and defibrotide
    Pol, R. R.
    Russell, N.
    Das-gupta, E.
    Watson, L.
    Rachael, L.
    Byrne, J.
    BONE MARROW TRANSPLANTATION, 2015, 50 : S35 - S35
  • [45] Gemtuzumab ozogamicinHepatic veno-occlusive disease: case report
    Reactions Weekly, 2007, 1175 (1) : 13 - 13
  • [46] Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results From the International Compassionate Use Program
    Corbacioglu, Selim
    Carreras, Enric
    Mohty, Mohamad
    Pagliuca, Antonio
    Boelens, Jaap Jan
    Damaj, Gandhi
    Iacobelli, Massimo
    Niederwieser, Dietger
    Olavarria, Eduardo
    Suarez, Felipe
    Ruutu, Tapani
    Verdonck, Leo
    Hume, Robin
    Nejadnik, Bijan
    Lai, Chinglin
    Finetto, Giorgia
    Richardson, Paul
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (10) : 1874 - 1882
  • [47] Defibrotide for the treatment of severe hepatic veno-occlusive disease/sinusoidal obstruction syndrome: evidence for clinical benefit
    Richardson, Paul G.
    Krishnan, Amrita
    Giralt, Sergio
    Soiffer, Robert J.
    EXPERT OPINION ON ORPHAN DRUGS, 2015, 3 (12): : 1491 - 1501
  • [48] Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment
    Wadleigh, M
    Ho, V
    Momtaz, P
    Richardson, P
    CURRENT OPINION IN HEMATOLOGY, 2003, 10 (06) : 451 - 462
  • [49] VENO-OCCLUSIVE DISEASE (VOD) ASSOCIATED WITH GEMTUZUMAB OZOGAMICIN (GO) AND INOTUZUMAB OZOGAMICIN: ANALYSIS OF THE FDA ADVERSE EVENT REPORTING SYSTEM
    Alsultan, M.
    Guo, J. J.
    Schwartz, R.
    VALUE IN HEALTH, 2018, 21 : S105 - S105
  • [50] Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation
    Corbacioglu, Selim
    Richardson, Paul G.
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2017, 11 (10) : 885 - 898
12345